GoAI
Get started
Forte Biosciences, Inc. logo

Forte Biosciences, Inc.

FBRX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$76.92

+$0.03 · +0.04%

Aug 21, 4:00 PM ET

FBRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

28

Expensive

Momentum

79

Gaining

Sentiment

45

Mixed

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Paul A. Wagner
Listed since
Apr 13, 2017
Employees
23

Market position

Day range

Current $76.92

52-week range

Current $76.92

Open
$76.94
Previous close
$76.89
Volume
2.01M
2.06× average
Average volume
975.45K
Average daily volume
Market cap
1.58B USD
Beta
2.65
Market reference 1
50-day average
$49.1786
+56.41% above average
200-day average
$31.2233
+146.35% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
324.38M USD
EV / EBITDA
-4.75×
Earnings yield
-17.29%
Free cash flow yield
-12.71%

Profitability & efficiency

Return on equity
-113.75%
Return on assets
-83.81%
Return on invested capital
-113.91%

Financial health

Current ratio
3.88×

Financial statements

Income trends

Operating income

−70.66M USD-93.04%

Net income

−69.38M USD-95.54%
Income trends across reported periods−8.18M USD−30.9M USD−53.62M USD−76.34M USDOperating income, FY2021: −21.49M USDOperating income, FY2022: −13.9M USDOperating income, FY2023: −32.49M USDOperating income, FY2024: −36.6M USDOperating income, FY2025: −70.66M USDNet income, FY2021: −21.71M USDNet income, FY2022: −13.86M USDNet income, FY2023: −31.48M USDNet income, FY2024: −35.48M USDNet income, FY2025: −69.38M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −21.49M USD. Operating income FY2022 −13.9M USD. Operating income FY2023 −32.49M USD. Operating income FY2024 −36.6M USD. Operating income FY2025 −70.66M USD. Net income FY2021 −21.71M USD. Net income FY2022 −13.86M USD. Net income FY2023 −31.48M USD. Net income FY2024 −35.48M USD. Net income FY2025 −69.38M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold64K USD39K USD9K USD—36K USD
Gross profit−64K USD−39K USD−9K USD—−36K USD
Research and development58.25M USD21.19M USD21.86M USD5.59M USD13.85M USD
Selling, general, and administrative12.41M USD15.37M USD10.62M USD8.3M USD7.63M USD
Operating expenses70.66M USD36.56M USD32.48M USD13.9M USD21.49M USD
Interest income2.72M USD1.31M USD1.12M USD——
Depreciation and amortization64K USD39K USD9K USD36K USD36K USD
Operating income−70.66M USD−36.6M USD−32.49M USD−13.9M USD−21.49M USD
Net income−69.38M USD−35.48M USD−31.48M USD−13.86M USD−21.71M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$77.00

0.10% upside
Past 12 months12-month forecastHigh $77.00Average $77.00Low $77.00

Rating distribution

7 ratings
Strong buy00%
Buy343%
Hold457%
Sell00%
Strong sell00%

FBRX news

gurufocus.com

Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?

Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 12, 2026

Read source
prnewswire.com

Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Read source
gurufocus.com

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propos

Read source
businesswire.com

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc.…

Read source
gurufocus.com

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash.Halper

Read source
businesswire.com

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash. Halper Sadeh encourages Forte…

Read source

FBRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding FBRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
47.72M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
37.48M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
16.68M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
13.98M
Weight
0.09%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
8.32M
Weight
0.05%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
5.13M
Weight
0.34%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Alger 35 ETF logoAlger 35 ETFATFV
Market value
4.58M
Weight
1.22%
AUM
257.79M USD
Expense ratio
0.56%
Price / 1D
$39.47+0.58%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
3.27M
Weight
0.05%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%

Continue in GoAI

Research FBRX

research.disclaimer